A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice

Antiviral Research

Volumn 90, Issue 1, 2011, Pages 17-21

  Bantia, Shanta ^a   Kellogg, Debra ^a   Parker, Cynthia ^a   Upshaw, Ramanda ^a   Ilyushina, Natalia A ^b   Babu, Y S ^a  

^a BIOCRYST PHARMACEUTICALS INC   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Influenza; Intramuscular; Mouse model; Pandemic; Peramivir

Indexed keywords

OSELTAMIVIR; PERAMIVIR;

2009 H1N1 INFLUENZA; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; LETHALITY; MORTALITY; PRIORITY JOURNAL; VIRUS SURVIVAL; WEIGHT REDUCTION;

ANIMALS; ANTIVIRAL AGENTS; BODY WEIGHT; CYCLOPENTANES; DISEASE MODELS, ANIMAL; FEMALE; GUANIDINES; INFLUENZA A VIRUS, H1N1 SUBTYPE; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RODENT DISEASES; SURVIVAL ANALYSIS;

INFLUENZA A VIRUS; MURINAE; MUS; ORTHOMYXOVIRIDAE; SUIDAE;

EID: 79953723442     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.02.001     Document Type: Article

References (20)

1. Babu Y.S., Chand P., Bantia S., Kotian P., Dehghani A., El-Kattan Y., Lin T.H., Hutchison T.L., Elliott A.J., Parker C.D., Ananth S.L., Horn L.L., Laver G.W., Montgomery J.A. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 2000, 43:3482-3486.
2. Bantia S., Parker C.D., Ananth S.L., Horn L.L., Andries K., Chand P., Kotian P.L., Dehghani A., El-Kattan Y., Lin T., Hutchison T.L., Montgomery J.A., Kellogg D.L., Babu Y.S. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 2001, 45:1162-1167.
3. Bantia S., Arnold C.S., Parker C.D., Upshaw R., Chand P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antivir. Res. 2006, 69:39-45.
4. Boltz D.A., Ilyushina N.A., Arnold C.S., Babu Y.S., Webster R.G., Govorkova E.A. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antivir. Res. 2008, 80:150-157.
5. CDC, 2009. Morbidity and Mortality Weekly Report, vol. 58, pp. 433-435.
6. Center for Drug Evaluation and Research, Pharmacology and Toxicology Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers 2005, U.S. Food and Drug Administration, Rockville, MD, USA.
7. Hayden F.G., Osterhaus A.D., Treanor J.J., Fleming D.M., Aoki F.Y., Nicholson K.G., Bohnen A.M., Hirst H.M., Keene O., Wightman K. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections GG167 Influenza Study Group. N. Engl. J. Med. 1997, 337:874-880.
8. Hayden F.G., Atmar R.L., Schilling M., Johnson C., Poretz D., Paar D., Huson L., Ward P., Mills R.G. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N. Engl. J. Med. 1999, 341:1336-1343.
9. Hernandez, J.E., Adiga, R., Armstrong, R., Bazan, J., Bonilla, H., Bradley, J., Dretler, R., Ison, M.G., Mangino, J.E., Maroushek, S., Shetty, A.K., Wald, A., Ziebold, C., Elder, J., Hollister, A.S., Sheridan, W., Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an emergency IND Program in the United States. Clin. Infect. Dis., in press, doi:10.1093/cid/cir001.
10. Ison M.G., McGeer A.J., Hui D.S., Clezy K., O'Neil B., Flynt A., Elder J., Simon T.J., Alexander W.J. Safety and efficacy of multiple-day treatment with intravenous peramivir or oral oseltamivir in hospitalized adults with acute influenza [abstr. V-6]. XI International Symposium on Respiratory Viral Infections, Oral abstract 2009.
11. Itoh Y., Shinya K., Kiso M., Watanabe T., Sakoda Y., Hatta M., Muramoto Y., Tamura D., Sakai-Tagawa Y., Noda T., Sakabe S., Imai M., Hatta Y., Watanabe S., Li C., Yamada S., Fujii K., Murakami S., Imai H., Kakugawa S., Ito M., Takano R., Iwatsuki-Horimoto K., Shimojima M., Horimoto T., Goto H., Takahashi K., Makino A., Ishigaki H., Nakayama M., Okamatsu M., Takahashi K., Warshauer D., Shult P.A., Saito R., Suzuki H., Furuta Y., Yamashita M., Mitamura K., Nakano K., Nakamura M., Brockman-Schneider R., Mitamura H., Yamazaki M., Sugaya N., Suresh M., Ozawa M., Neumann G., Gern J., Kida H., Ogasawara K., Kawaoka Y. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009, 460:1021-1025.
12. Ilyushina N.A., Khalenkov A.M., Seiler J.P., Forrest H.L., Bovin N.V., Marjuki H., Barman S., Webster R.G., Webby R.J. Adaptation of pandemic H1N1 influenza viruses in mice. J. Virol. 2010, 84:8607-8616.
13. Johansson B.E., Grajower B., Kilbourne E.D. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine 1993, 11:1037-1039.
14. Kaiser L., Wat C., Mills T., Mahoney P., Ward P., Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch. Intern. Med. 2003, 163:1667-1672.
15. Kohno S., Yen M.Y., Cheong H.J., Hirotsu N., Ishida T., Kadota J., Mizuguchi M., Kida H., Shimada J. Single-intravenous peramivir vs. oral oseltamivir to treat acute, uncomplicated influenza in the outpatient setting: a phase III randomized, double-blind trial. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009) 2009.
16. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., Gubareva L.V., Xu X., Bridges C.B., Uyeki T.M. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 2009, 360:2605-2615.
17. Potier M., Mameli L., Bélisle M., Dallaire L., Melançon S.B. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α-d-N-acetylneuraminate) substrate. Anal. Biochem. 1979, 94:287-296.
18. Sidwell R.W., Smee D.F., Huffman J.H., Barnard D.L., Morrey J.D., Bailey K.W., Feng W.C., Babu Y.S., Bush K. Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201. Antivir. Res. 2001, 51:179-187.
19. Tarbet E.B., Hurst B.L., Barnard D.L., Babu Y.S., Furuta Y., Smee D.F. Antiviral drug efficacy evaluation against pandemic influenza (H1N1) viruses in MDCK cells. 23rd ICAR Abstract Issue/Antiviral Research 86, abstract # 104 2010.
20. Yun N.E., Linde N.S., Zacks M.A., Barr I.G., Hurt A.C., Smith J.N., Dziuba N., Holbrook M.R., Zhang L., Kilpatrick J.M., Arnold C.S., Paessler S. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus A/Vietnam/1203/04 (H5N1). Virology 2008, 374:198-209.